164 related articles for article (PubMed ID: 12620508)
1. R-citalopram attenuates anxiolytic effects of escitalopram in a rat ultrasonic vocalisation model.
Sánchez C
Eur J Pharmacol; 2003 Mar; 464(2-3):155-8. PubMed ID: 12620508
[TBL] [Abstract][Full Text] [Related]
2. Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic activities.
Sánchez C; Bergqvist PB; Brennum LT; Gupta S; Hogg S; Larsen A; Wiborg O
Psychopharmacology (Berl); 2003 Jun; 167(4):353-62. PubMed ID: 12719960
[TBL] [Abstract][Full Text] [Related]
3. [Mechanisms of action of antidepressants: new data from Escitalopram].
Fabre V; Hamon M
Encephale; 2003; 29(3 Pt 1):259-65. PubMed ID: 12876551
[TBL] [Abstract][Full Text] [Related]
4. [Escitalopram: a selective inhibitor and allosteric modulator of the serotonin transporter].
Mnie-Filali O; El Mansari M; Scarna H; Zimmer L; Sánchez C; Haddjeri N
Encephale; 2007 Dec; 33(6):965-72. PubMed ID: 18789789
[TBL] [Abstract][Full Text] [Related]
5. R-citalopram inhibits functional and 5-HTP-evoked behavioural responses to the SSRI, escitalopram.
Sánchez C; Kreilgaard M
Pharmacol Biochem Behav; 2004 Feb; 77(2):391-8. PubMed ID: 14751469
[TBL] [Abstract][Full Text] [Related]
6. Stress-induced vocalisation in adult animals. A valid model of anxiety?
Sánchez C
Eur J Pharmacol; 2003 Feb; 463(1-3):133-43. PubMed ID: 12600706
[TBL] [Abstract][Full Text] [Related]
7. R-citalopram counteracts the antidepressant-like effect of escitalopram in a rat chronic mild stress model.
Sánchez C; Gruca P; Papp M
Behav Pharmacol; 2003 Sep; 14(5-6):465-70. PubMed ID: 14501259
[TBL] [Abstract][Full Text] [Related]
8. The role of 5-HT receptor subtypes in the anxiolytic effects of selective serotonin reuptake inhibitors in the rat ultrasonic vocalization test.
Schreiber R; Melon C; De Vry J
Psychopharmacology (Berl); 1998 Feb; 135(4):383-91. PubMed ID: 9539263
[TBL] [Abstract][Full Text] [Related]
9. Allosteric modulation of the effect of escitalopram, paroxetine and fluoxetine: in-vitro and in-vivo studies.
Mansari ME; Wiborg O; Mnie-Filali O; Benturquia N; Sánchez C; Haddjeri N
Int J Neuropsychopharmacol; 2007 Feb; 10(1):31-40. PubMed ID: 16448580
[TBL] [Abstract][Full Text] [Related]
10. The effects of the co-administration of the α₁-adrenoreceptor antagonist prazosin on the anxiolytic effect of citalopram in conditioned fear stress in the rat.
Takamura N; Masuda T; Inoue T; Nakagawa S; Koyama T
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Oct; 39(1):107-11. PubMed ID: 22658980
[TBL] [Abstract][Full Text] [Related]
11. Protein Kinases Alter the Allosteric Modulation of the Serotonin Transporter In Vivo and In Vitro.
Mnie-Filali O; Lau T; Matthaeus F; Abrial E; Delcourte S; El Mansari M; Pershon A; Schloss P; Sánchez C; Haddjeri N
CNS Neurosci Ther; 2016 Aug; 22(8):691-9. PubMed ID: 27171685
[TBL] [Abstract][Full Text] [Related]
12. Effects of S-citalopram, citalopram, and R-citalopram on the firing patterns of dopamine neurons in the ventral tegmental area, N-methyl-D-aspartate receptor-mediated transmission in the medial prefrontal cortex and cognitive function in the rat.
Schilström B; Konradsson-Geuken A; Ivanov V; Gertow J; Feltmann K; Marcus MM; Jardemark K; Svensson TH
Synapse; 2011 May; 65(5):357-67. PubMed ID: 20730799
[TBL] [Abstract][Full Text] [Related]
13. Shock-induced ultrasonic vocalization in young adult rats: a model for testing putative anti-anxiety drugs.
De Vry J; Benz U; Schreiber R; Traber J
Eur J Pharmacol; 1993 Nov; 249(3):331-9. PubMed ID: 7904565
[TBL] [Abstract][Full Text] [Related]
14. Shock priming enhances the efficacy of SSRIs in the foot shock-induced ultrasonic vocalization test.
Kassai F; Gyertyán I
Prog Neuropsychopharmacol Biol Psychiatry; 2012 Jan; 36(1):128-35. PubMed ID: 22041499
[TBL] [Abstract][Full Text] [Related]
15. Neurokinin1 antagonists potentiate antidepressant properties of serotonin reuptake inhibitors, yet blunt their anxiogenic actions: a neurochemical, electrophysiological, and behavioral characterization.
Gobert A; Brocco M; Dekeyne A; Di Cara B; Bouchez G; Lejeune F; Gannon RL; Millan MJ
Neuropsychopharmacology; 2009 Mar; 34(4):1039-56. PubMed ID: 18830239
[TBL] [Abstract][Full Text] [Related]
16. Anxiolytic-like effects of escitalopram, citalopram, and R-citalopram in maternally separated mouse pups.
Fish EW; Faccidomo S; Gupta S; Miczek KA
J Pharmacol Exp Ther; 2004 Feb; 308(2):474-80. PubMed ID: 14593091
[TBL] [Abstract][Full Text] [Related]
17. An allosteric binding site at the human serotonin transporter mediates the inhibition of escitalopram by R-citalopram: kinetic binding studies with the ALI/VFL-SI/TT mutant.
Zhong H; Hansen KB; Boyle NJ; Han K; Muske G; Huang X; Egebjerg J; Sánchez C
Neurosci Lett; 2009 Oct; 462(3):207-12. PubMed ID: 19616061
[TBL] [Abstract][Full Text] [Related]
18. Target brain sites of the anxiolytic effect of citalopram, a selective serotonin reuptake inhibitor.
Izumi T; Inoue T; Kitaichi Y; Nakagawa S; Koyama T
Eur J Pharmacol; 2006 Mar; 534(1-3):129-32. PubMed ID: 16494863
[TBL] [Abstract][Full Text] [Related]
19. The effects of acute treatment with escitalopram on the different stages of contextual fear conditioning are reversed by atomoxetine.
Montezinho LP; Miller S; Plath N; Jensen NH; Karlsson JJ; Witten L; Mørk A
Psychopharmacology (Berl); 2010 Oct; 212(2):131-43. PubMed ID: 20676614
[TBL] [Abstract][Full Text] [Related]
20. 17β-Estradiol augments antidepressant efficacy of escitalopram in ovariectomized rats: Neuroprotective and serotonin reuptake transporter modulatory effects.
Ibrahim WW; Safar MM; Khattab MM; Agha AM
Psychoneuroendocrinology; 2016 Dec; 74():240-250. PubMed ID: 27685339
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
